Phenylpropanolamine
Overview of Phenylpropanolamine

Phenylpropanolamine (PPA) is a sympathomimetic agent used as a decongestant and appetite suppressant. It is a member of the phenethylamine class and is structurally related to ephedrine and amphetamine.
Pharmacology[edit]
Phenylpropanolamine acts primarily as an alpha-adrenergic receptor agonist, leading to vasoconstriction and decreased nasal congestion. It also has some activity as a beta-adrenergic receptor agonist, which contributes to its effects on appetite suppression.
Medical Uses[edit]
Phenylpropanolamine was commonly used in over-the-counter cold medications and weight loss products. It was effective in reducing nasal congestion and suppressing appetite.
Safety and Regulation[edit]
In the early 2000s, concerns about the safety of phenylpropanolamine led to its withdrawal from the market in many countries. Studies indicated an increased risk of hemorrhagic stroke in women using the drug. As a result, the U.S. Food and Drug Administration (FDA) issued a public health advisory in 2000, recommending that consumers not use products containing phenylpropanolamine.
Current Status[edit]
Phenylpropanolamine is no longer available in the United States and many other countries for human use. However, it is still used in veterinary medicine, particularly for the treatment of urinary incontinence in dogs.
Mechanism of Action[edit]
Phenylpropanolamine works by stimulating the release of norepinephrine and dopamine from nerve terminals, which leads to increased adrenergic activity. This results in vasoconstriction and reduced blood flow to the nasal passages, alleviating congestion.
Side Effects[edit]
Common side effects of phenylpropanolamine include increased heart rate, elevated blood pressure, anxiety, dizziness, and insomnia. Due to its stimulant effects, it can also lead to tachycardia and hypertension.
History[edit]
Phenylpropanolamine was first introduced in the 1930s and became widely used in the 1970s and 1980s. Its popularity declined after safety concerns emerged, leading to regulatory actions in the 1990s and 2000s.
Also see[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


